Barclays’s Medpace MEDP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $13.7M | Sell |
25,775
-36,932
| -59% | -$17M | ﹤0.01% | 1326 |
|
|
2026
Q1 | $30.1M | Buy |
62,707
+32,660
| +109% | +$16.7M | 0.01% | 935 |
|
|
2025
Q4 | $16.9M | Buy |
30,047
+1,828
| +6% | +$1.04M | ﹤0.01% | 1343 |
|
|
2025
Q3 | $14.5M | Buy |
28,219
+7,585
| +37% | +$3.31M | ﹤0.01% | 1405 |
|
|
2025
Q2 | $6.48M | Sell |
20,634
-3,282
| -14% | -$985K | ﹤0.01% | 1897 |
|
|
2025
Q1 | $7.29M | Sell |
23,916
-4,250
| -15% | -$1.43M | ﹤0.01% | 1628 |
|
|
2024
Q4 | $9.36M | Buy |
28,166
+8,385
| +42% | +$2.84M | ﹤0.01% | 1621 |
|
|
2024
Q3 | $6.6M | Buy |
19,781
+8,275
| +72% | +$3.14M | ﹤0.01% | 1828 |
|
|
2024
Q2 | $4.74M | Sell |
11,506
-19,634
| -63% | -$7.78M | ﹤0.01% | 1572 |
|
|
2024
Q1 | $12.6M | Buy |
31,140
+3,722
| +14% | +$1.31M | ﹤0.01% | 1235 |
|
|
2023
Q4 | $8.4M | Buy |
27,418
+10,521
| +62% | +$2.84M | ﹤0.01% | 1648 |
|
|
2023
Q3 | $4.09M | Sell |
16,897
-7,583
| -31% | -$1.94M | ﹤0.01% | 1449 |
|
|
2023
Q2 | $5.88M | Buy |
24,480
+3,283
| +15% | +$682K | ﹤0.01% | 1259 |
|
|
2023
Q1 | $3.99M | Buy |
21,197
+1,565
| +8% | +$324K | ﹤0.01% | 1704 |
|
|
2022
Q4 | $4.17M | Sell |
19,632
-6,460
| -25% | -$1.29M | ﹤0.01% | 1754 |
|
|
2022
Q3 | $4.1M | Buy |
26,092
+14,963
| +134% | +$2.39M | ﹤0.01% | 1284 |
|
|
2022
Q2 | $1.67M | Sell |
11,129
-8,893
| -44% | -$1.29M | ﹤0.01% | 1980 |
|
|
2022
Q1 | $3.28M | Sell |
20,022
-24,437
| -55% | -$4.03M | ﹤0.01% | 1485 |
|
|
2021
Q4 | $9.68M | Buy |
44,459
+18,105
| +69% | +$3.79M | ﹤0.01% | 1285 |
|
|
2021
Q3 | $4.99M | Buy |
26,354
+1,940
| +8% | +$354K | ﹤0.01% | 1645 |
|
|
2021
Q2 | $4.31M | Buy |
24,414
+85
| +0.3% | +$14.7K | ﹤0.01% | 1686 |
|
|
2021
Q1 | $3.99M | Sell |
24,329
-16,679
| -41% | -$2.55M | ﹤0.01% | 1714 |
|
|
2020
Q4 | $5.71M | Sell |
41,008
-41,602
| -50% | -$5.24M | ﹤0.01% | 1443 |
|
|
2020
Q3 | $9.23M | Buy |
82,610
+41,015
| +99% | +$4.74M | 0.01% | 1063 |
|
|
2020
Q2 | $3.87M | Buy |
41,595
+2,110
| +5% | +$180K | ﹤0.01% | 1559 |
|
|
2020
Q1 | $2.9M | Sell |
39,485
-17,934
| -31% | -$1.56M | ﹤0.01% | 1931 |
|
|
2019
Q4 | $4.83M | Buy |
57,419
+14,700
| +34% | +$1.14M | ﹤0.01% | 2043 |
|
|
2019
Q3 | $3.59M | Buy |
42,719
+4,671
| +12% | +$353K | ﹤0.01% | 2182 |
|
|
2019
Q2 | $2.49M | Buy |
38,048
+16,747
| +79% | +$965K | ﹤0.01% | 2651 |
|
|
2019
Q1 | $1.26M | Sell |
21,301
-15,245
| -42% | -$911K | ﹤0.01% | 3148 |
|
|
2018
Q4 | $1.93M | Buy |
36,546
+9,693
| +36% | +$532K | ﹤0.01% | 2443 |
|
|
2018
Q3 | $1.61M | Buy |
26,853
+6,693
| +33% | +$366K | ﹤0.01% | 3136 |
|
|
2018
Q2 | $866K | Sell |
20,160
-30,601
| -60% | -$1.24M | ﹤0.01% | 3444 |
|
|
2018
Q1 | $1.77M | Buy |
50,761
+22,683
| +81% | +$829K | ﹤0.01% | 2587 |
|
|
2017
Q4 | $1.02M | Sell |
28,078
-4,190
| -13% | -$147K | ﹤0.01% | 3094 |
|
|
2017
Q3 | $1.03M | Sell |
32,268
-2,937
| -8% | -$89.7K | ﹤0.01% | 2973 |
|
|
2017
Q2 | $1.02M | Buy |
35,205
+16,921
| +93% | +$475K | ﹤0.01% | 2868 |
|
|
2017
Q1 | $546K | Buy |
18,284
+18,018
| +6,774% | +$582K | ﹤0.01% | 3312 |
|
|
2016
Q4 | $9K | Sell |
266
-7,062
| -96% | -$235K | ﹤0.01% | 5938 |
|
|
2016
Q3 | $219K | Buy |
+7,328
| New | +$214K | ﹤0.01% | 3901 |
|
Other funds holding MEDP
WA
Barclays's MEDP Position: Q2 2026 in Review
Barclays reduced its Medpace (MEDP) stake by 59% in Q2 2026, selling an estimated $17M and leaving 25,775 shares worth $13.7M. The position accounts for ﹤0.01% of the portfolio, ranked #1326.
Barclays first reported a position in MEDP in Q3 2016 and has held it in 40 quarters since. The position peaked at $30.1M in Q1 2026. 697 funds tracked by Wall St. Rank hold MEDP as of Q2 2026.
- Barclays held 25,775 shares of Medpace worth $13.7M as of Q2 2026.
- Barclays sold 36,932 Medpace shares in Q2 2026, an estimated $17M.
- Medpace made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #1326 holding.
- Barclays first reported a position in Medpace in Q3 2016 and has held it in 40 quarters since.
- Barclays's Medpace position peaked at $30.1M in Q1 2026.
- 697 funds tracked by Wall St. Rank held Medpace as of Q2 2026.
Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.